Baidu
map

Cell:肿瘤干细胞的新生物标志物多巴胺受体

2012-05-25 Beyond 生物谷

一种用于治疗精神分裂症的抗精神病的药物通过帮助癌症干细胞分化成威胁性较低的细胞类型,似乎也作用于癌症干细胞。5月24日的Cell杂志上刊登的一则研究报道:为了寻找能选择性地抑制人类癌症干细胞,研究人员筛选了数百种化合物,这一研究成果可能会很快走上临床试验。 麦克马斯特大学Mickie Bhatia,论文的主要作者说:你必须找到那些能真正选择性作用于癌症干细胞的药物,我们研究工作进行一段时间后,发

一种用于治疗精神分裂症的抗精神病的药物通过帮助癌症干细胞分化成威胁性较低的细胞类型,似乎也作用于癌症干细胞。5月24日的Cell杂志上刊登的一则研究报道:为了寻找能选择性地抑制人类癌症干细胞,研究人员筛选了数百种化合物,这一研究成果可能会很快走上临床试验。

麦克马斯特大学Mickie Bhatia,论文的主要作者说:你必须找到那些能真正选择性作用于癌症干细胞的药物,我们研究工作进行一段时间后,发现很难找到确切的物质。

近30年以来,癌症患者的生存很大程度上是不变的。通过解决数量上少以及化疗耐药的肿瘤干细胞,很多人相信癌症治疗会取得更大成就。

与正常的干细胞不一样,癌症干细胞分化成稳定地、未分化的细胞类型的趋势不明显。Bhatia的研究小组利用癌症干细胞的这种差异性,进行了活性化合物的筛选工作。
 
通过测试数百种化合物,他们确定了近20个潜在的癌症干细胞特异性药物。其中一个似乎最有前途的就是抗精神病药物——硫利达嗪。硫利达嗪是众所周知的针对大脑中的多巴胺受体,治疗精神分裂症的药物。这种药物不会杀死癌症干细胞,但却能促进干细胞分化,从而耗尽细胞的自我更新。
 
研究人员发现,硫利达嗪在杀死白血病干细胞的同时,而不影响正常的血液干细胞。通过比较白血病与正常血细胞的蛋白质,研究人员解释这一药物的特异性。白血病细胞在其表面表达多巴胺受体,但正常的造血干细胞不表达。研究人员还发现多巴胺受体也在一些乳腺癌干细胞上表达。

Bhatia说,这提示我们多巴胺受体可能作为肿瘤干细胞的生物标志物。
 
鉴于研究结果,Bhatia的团队正申请一项旨在FDA批准的硫利达嗪与标准抗癌药物相结合的治疗成人急性髓细胞性白血病的临床试验。

doi:10.1016/j.cell.2012.03.049
PMC:
PMID:

Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells

Eleftherios Sachlos, Ruth M. Risue?o, Sarah Laronde, Zoya Shapovalova, Jong-Hee Lee, Jennifer Russell, Monika Malig, Jamie D. McNicol, Aline Fiebig-Comyn, Monica Graham, Marilyne Levadoux-Martin, Jung Bok Lee, Andrew O. Giacomelli, John A. Hassell, Daniela Fischer-Russell, Michael R. Trus, Ronan Foley, Brian Leber, Anargyros Xenocostas, Eric D. Brown, Tony J. Collins, Mickie Bhatia.

Selective targeting of cancer stem cells (CSCs) offers promise for a new generation of therapeutics. However, assays for both human CSCs and normal stem cells that are amenable to robust biological screens are limited. Using a discovery platform that reveals differences between neoplastic and normal human pluripotent stem cells (hPSC), we identify small molecules from libraries of known compounds that induce differentiation to overcome neoplastic self-renewal. Surprisingly, thioridazine, an antipsychotic drug, selectively targets the neoplastic cells, and impairs human somatic CSCs capable of in vivo leukemic disease initiation while having no effect on normal blood SCs. The drug antagonizes dopamine receptors that are expressed on CSCs and on breast cancer cells as well. These results suggest that dopamine receptors may serve as a biomarker for diverse malignancies, demonstrate the utility of using neoplastic hPSCs for identifying CSC-targeting drugs, and provide support for the use of differentiation as a therapeutic strategy.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1923999, encodeId=326c192399944, content=<a href='/topic/show?id=4f754322561' target=_blank style='color:#2F92EE;'>#多巴胺受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43225, encryptionId=4f754322561, topicName=多巴胺受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Jan 24 04:57:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840738, encodeId=64621840e380d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 17 21:57:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868519, encodeId=919e186851900, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 28 07:57:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958750, encodeId=b7c81958e50ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 20:57:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560499, encodeId=f456156049939, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566508, encodeId=a723156650864, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1923999, encodeId=326c192399944, content=<a href='/topic/show?id=4f754322561' target=_blank style='color:#2F92EE;'>#多巴胺受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43225, encryptionId=4f754322561, topicName=多巴胺受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Jan 24 04:57:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840738, encodeId=64621840e380d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 17 21:57:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868519, encodeId=919e186851900, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 28 07:57:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958750, encodeId=b7c81958e50ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 20:57:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560499, encodeId=f456156049939, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566508, encodeId=a723156650864, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1923999, encodeId=326c192399944, content=<a href='/topic/show?id=4f754322561' target=_blank style='color:#2F92EE;'>#多巴胺受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43225, encryptionId=4f754322561, topicName=多巴胺受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Jan 24 04:57:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840738, encodeId=64621840e380d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 17 21:57:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868519, encodeId=919e186851900, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 28 07:57:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958750, encodeId=b7c81958e50ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 20:57:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560499, encodeId=f456156049939, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566508, encodeId=a723156650864, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1923999, encodeId=326c192399944, content=<a href='/topic/show?id=4f754322561' target=_blank style='color:#2F92EE;'>#多巴胺受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43225, encryptionId=4f754322561, topicName=多巴胺受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Jan 24 04:57:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840738, encodeId=64621840e380d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 17 21:57:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868519, encodeId=919e186851900, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 28 07:57:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958750, encodeId=b7c81958e50ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 20:57:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560499, encodeId=f456156049939, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566508, encodeId=a723156650864, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
    2013-02-02 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1923999, encodeId=326c192399944, content=<a href='/topic/show?id=4f754322561' target=_blank style='color:#2F92EE;'>#多巴胺受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43225, encryptionId=4f754322561, topicName=多巴胺受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Jan 24 04:57:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840738, encodeId=64621840e380d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 17 21:57:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868519, encodeId=919e186851900, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 28 07:57:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958750, encodeId=b7c81958e50ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 20:57:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560499, encodeId=f456156049939, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566508, encodeId=a723156650864, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1923999, encodeId=326c192399944, content=<a href='/topic/show?id=4f754322561' target=_blank style='color:#2F92EE;'>#多巴胺受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43225, encryptionId=4f754322561, topicName=多巴胺受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Jan 24 04:57:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840738, encodeId=64621840e380d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Oct 17 21:57:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868519, encodeId=919e186851900, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 28 07:57:00 CST 2013, time=2013-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958750, encodeId=b7c81958e50ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 02 20:57:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560499, encodeId=f456156049939, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566508, encodeId=a723156650864, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]

相关资讯

Science:新近发现甘氨酸与癌细胞的增殖相关

近一个世纪以来,研究人员已经知道癌细胞不同于正常细胞,其葡萄糖代谢方式发生了变化。近日,Broad研究所和马萨诸塞州总医院的研究人员研究了60种肿瘤细胞株,分析了肿瘤细胞处于细胞分裂期时,超过200多种肿瘤细胞消耗或释放的代谢产物。研究发现最小的氨基酸——甘氨酸在癌细胞扩散中发挥关键作用。其研究结果刊登在5月25日的国际权威杂志Science上。 Vamsi Moothas表示:科学家们对癌症新

Cancer Cell:S1PR1-STAT3激活促进骨髓样细胞的促肿瘤转移作用

近来研究表明,骨髓样细胞可使远处器官易于接受扩散肿瘤细胞的集落形成。然而,其具体机制一直不明。5月14日Cancer Cell报道了Hua Yu研究组的论文"S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites"揭示了其分子机制。   研究者发现,在肿瘤细胞中

Lancet:新药dabrafenib或可安全有效地治疗黑色素瘤

一项针对黑色素瘤中常见基因突变的实验性药物研究证实,药物dabrafenib成功地缩小了发生脑转移的黑色素瘤患者的肿瘤病灶,有效率达90%。这项国际临床I期药物试验研究发表在5月18日的国际著名杂志《柳叶刀》(The Lancet)上。 BRAF基因编码丝氨酸/苏氨酸蛋白激酶B-Raf,与细胞生长调控密切相关。在黑色素瘤中,BRAF常常突变引发细胞生长调控紊乱。Dabrafenib针对突变型BR

Sci Transl Med:daclizumab调控调节性T细胞促进肿瘤免疫治疗

调节性T细胞(Tregs)通过防止免疫细胞攻击自身机体对于人体健康有着重要作用。但是,在肿瘤微环境中Tregs细胞却抑制针对肿瘤细胞的免疫反应。由于Tregs 细胞表面表达CD25,Rech等人认为针对CD25的单抗免疫抑制药物daclizumab也许可以清除Tregs 细胞,从而恢复抗肿瘤免疫反应。 他们的假说得到了证实。5月16日国际著名转化医学杂志Science Translational

JCI:康铁邦团队发现新的肝细胞癌治疗靶点CHK1/SYK(L)

近日,来自中山大学肿瘤防治中心的康铁邦教授及其团队发现,在肝细胞癌中,CHK1靶向脾酪氨酸激酶能够促进其水解,则靶向CHK1/SYK(L)通路能成为一个很有潜力的HCC治疗策略。 肝细胞癌(HCC)是目前最流行的恶性肿瘤之一,能够顽强抵抗化疗或放疗。因此,确定HCC新的治疗靶点更是迫在眉睫。 在这项研究里,他们发现,HCC患者的细胞周期检测点激酶1(CHK1)被频繁的过表达,而且这与不良预后结

PLoS ONE:靶向FGFR4能够抑制肝细胞癌

近日,来自美国基因泰克公司的研究人员表示,靶向FGFR4能够抑制肝细胞癌。 成纤维细胞生长因子(FGF)是由垂体和下丘脑分泌的多肽,能促进成纤维细胞有丝分裂、中胚层细胞的生长,还可刺激血管形成,在创伤愈合及肢体再生中发挥重要作用。 FGF受体(FGFR)信号系统对正常的发育及生理过程具有至关重要的作用。业已证明,FGF-FGFR信号失调与肿瘤发生及演化息息相关。在老鼠体内,FGFR4–FGF1

Baidu
map
Baidu
map
Baidu
map